Shots:
1ST Biotherapeutics SK Biopharmaceuticals have entered into an exclusive global licensing agreement & strategic equity investment partnership to advance 1ST-104 for the treatment of Parkinson's disease
As per the deal, 1STBIO will receive a $1.8M upfront payment, with the licensing agreement valued at ~$314.8M, incl. a $1.8M short-term milestone upon candidate selection & additional…
